EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Genetic-Guided Oral P2Y12 Inhibitor Selection and Cumulative Ischemic Events After Percutaneous Coronary Intervention

Brenden S Ingraham, Michael E Farkouh, Ryan J Lennon, Derek So, Shaun G Goodman, Nancy Geller, Jang-Ho Bae, Myung Ho Jeong, Linnea M Baudhuin, Verghese Mathew, Malcolm R Bell, Amir Lerman und 9 weitere

JACC: Cardiovascular Interventions · 2023-04 · 16 (7) · 816-825

DOI: 10.1016/j.jcin.2023.01.356 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2023-04. Verfasst von Brenden S Ingraham und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Coronary Artery Disease, Acute Coronary Syndrome. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Genetic-guided P2Y12 inhibitor selection has been proposed to reduce ischemic events by identifying CYP2C19 loss-of-function (LOF) carriers at increased risk with clopidogrel treatment after percutaneous coronary intervention (PCI). A prespecified analysis of TAILOR-PCI (Tailored Antiplatelet Therapy Following PCI) evaluated the effect of genetic-guided P2Y12 inhibitor therapy on cumulative ischemic and bleeding events. OBJECTIVES: Here, the authors detail a prespecified analysis of cumulative endpoints. The primary endpoint was cumulative incidence rate of ischemic events at 12 months. Cumulative incidence of major and minor bleeding was a secondary endpoint. Cox proportional hazards models as adapted by Wei, Lin, and Weissfeld were used to estimate the effect of this strategy on all observed events. METHODS: The TAILOR-PCI trial was a prospective trial including 5,302 post-PCI patients with acute and stable coronary artery disease (CAD) who were randomized to genetic-guided P2Y12 inhibitor or conventional clopidogrel therapy. In the genetic-guided group, LOF carriers were prescribed ticagrelor, whereas noncarriers received clopidogrel. TAILOR-PCI's primary analysis was time to first event in LOF carriers. RESULTS: Among 5,276 patients (median age 62 years; 25% women; 82% acute CAD; 18% stable CAD), 1,849 were LOF carriers (903 genetic-guided; 946 conventional therapy). The cumulative primary endpoint was significantly reduced in the genetic-guided group compared with the conventional therapy (HR: 0.61; 95% CI: 0.41-0.89; P = 0.011) with no significant difference in cumulative incidence of major or minor bleeding (HR: 1.36; 95% CI: 0.67-2.76; P = 0.39). CONCLUSIONS: Among CYP2C19 LOF carriers undergoing PCI, a genetic-guided strategy resulted in a statistically significant reduction in cumulative ischemic events without a significant difference in bleeding. (Tailored Antiplatelet Therapy Following PCI [TAILOR-PCI]; NCT01742117).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionCoronary Artery DiseaseAcute Coronary SyndromeHumansFemaleMiddle AgedMaleClopidogrelPlatelet Aggregation InhibitorsCytochrome P-450 CYP2C19Prospective StudiesTreatment OutcomeHemorrhagePurinergic P2Y Receptor Antagonists

Stichwörter der Autor:innen

P2Y(12) inhibitorantiplatelet therapygenomicsindividualized medicinepercutaneous coronary intervention

Substanzen

ClopidogrelPlatelet Aggregation InhibitorsCytochrome P-450 CYP2C19Purinergic P2Y Receptor Antagonists

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Peter Munk Cardiac Centre and Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, Ontario, Canada.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
  • St. Michael's Hospital, University of Toronto, Toronto, Canada; Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada.
  • National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Ingraham, B. S., Farkouh, M. E., Lennon, R. J., So, D., Goodman, S. G., Geller, N., Bae, J. H., Jeong, M. H., Baudhuin, L. M., Mathew, V., Bell, M. R., Lerman, A., Fu, Y. P., Hasan, A., Iturriaga, E., Tanguay, J. F., Welsh, R. C., Rosenberg, Y., Bailey, K., …, & Pereira, N. L. (2023). Genetic-Guided Oral P2Y12 Inhibitor Selection and Cumulative Ischemic Events After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 16(7), 816-825. https://doi.org/10.1016/j.jcin.2023.01.356

Vancouver

Ingraham BS, Farkouh ME, Lennon RJ, So D, Goodman SG, Geller N, et al. Genetic-Guided Oral P2Y12 Inhibitor Selection and Cumulative Ischemic Events After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions. 2023;16(7):816-825. doi:10.1016/j.jcin.2023.01.356

BibTeX
@article{Ingraham2023,
  author = {Ingraham, Brenden S and Farkouh, Michael E and Lennon, Ryan J and So, Derek and Goodman, Shaun G and Geller, Nancy and Bae, Jang-Ho and Jeong, Myung Ho and Baudhuin, Linnea M and Mathew, Verghese and Bell, Malcolm R and Lerman, Amir and Fu, Yi-Ping and Hasan, Ahmed and Iturriaga, Erin and Tanguay, Jean-Francois and Welsh, Robert C and Rosenberg, Yves and Bailey, Kent and Rihal, Charanjit and Pereira, Naveen L},
  title = {Genetic-Guided Oral P2Y12 Inhibitor Selection and Cumulative Ischemic Events After Percutaneous Coronary Intervention},
  journal = {JACC: Cardiovascular Interventions},
  year = {2023},
  volume = {16},
  number = {7},
  pages = {816--825},
  doi = {10.1016/j.jcin.2023.01.356}
}
Kostenlos starten →